A Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA)

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA)

A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study. Following a 6-8 week placebo and dietary-controlled baseline period, approximately 195 men and women with either hypertriglyceridemia or mixed hyperlipidemia with serum triglycerides (TG) > 200 mg/dl (2.26 mmol/l) will be randomized to receive either placebo, 30 mg 1-MNA or 90 mg 1-MNA three times daily for twelve weeks. Lipid and ancillary exploratory parameters will be evaluated at screening, during the baseline period, upon randomisation and throughout the 12-week active treatment period. Additionally, blood samples will be drawn at randomisation and at clinic visits during the active treatment period for sparse sampling population pharmacokinetic assessments. All blood samples for lipid assessments and glucose measurements will be collected following a 12-hour fast. Safety and tolerability will be assessed throughout the trial through the evaluation of physical exams, ECGs, routine hematology and blood chemistry testing, and adverse events.

Study Overview

• Status: Completed
• Conditions: Hypertriglyceridemia
• Intervention / Treatment: Dietary supplement: Placebo; Dietary supplement: 1-Methylnicotinamide (1-MNA)

• Study Type: Interventional
• Enrollment (Anticipated): 195
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• Canada
  • Quebec
    • Montreal, Quebec, Canada, H1T 1C8
      • Institut de Cardiologie de Montreal

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients at least 18 years of age at the time of informed consent (women of childbearing potential must be practicing adequate contraception)
• Patients with mean serum TG > 200 mg/dl (2.26 mmol/l) and < 700 mg/dl (7.91 mmol/l) as measured at 2 sequential visits during the dietary controlled baseline period (Visits 2 and 3 or Visits 3 and 3a) and having lower level within 25% of upper level (higher value minus lower value)/higher value < 0.25)
• Patients willing and able to sign an informed consent form and follow the protocol

Exclusion Criteria:

• Patients who are pregnant or nursing
• Patients with evidence of hepatic (ALT or AST greater than 1.5 ULN, bilirubin greater than 1.5 ULN, or cirrhosis) or renal dysfunction (serum creatinine greater than 140 μmol/l, or nephrotic syndrome) as measured during the baseline phase
• Patients with uncontrolled diabetes mellitus (fasting glucose level above 11 mmol/l or HbA1C above 10%) as measured during the baseline phase
• Patients with hypothyroidism that is not treated or not stable for at least 6 months prior to study entry
• Patients with uncontrolled hypertension (systolic blood pressure above 160 mm Hg and/or diastolic blood pressure above 110 mm Hg)

• Patients with systolic blood pressure above 140 mm Hg AND three or more of the following cardiovascular risk factors:

  • Current cigarette smoker
  • HDL-C < 40 mg/dL (1.04 mmol/L)
  • Coronary heart disease in male first degree relative < 55 years of age
  • Coronary heart disease in female first degree relative < 65 years of age
  • Male age 45 years or older
  • Female age 55 years or older
• Patients with known hyperuricemia or with a history of gout
• Patients with an active peptic ulcer
• Patients with known coronary artery disease, cerebrovascular disease or peripheral arterial disease that has previously required PCI or surgical intervention
• Patients with known intolerance or allergy to niacin
• Patients consuming more than 10 alcoholic drinks per week
• Patients with a history of drug abuse
• Patients receiving any lipid modifying agent within 4 weeks of entry into the baseline period
• Patients participating in another clinical trial within 30 days of entry into the baseline period
• Patients considered to be non-compliant to study medication (< 80% study medication) or diet during the placebo-baseline phase
• Patients for whom the investigator determines that the study would not be appropriate

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: 1; three placebo capsules PO three times daily.	Dietary supplement: Placebo; Placebo
Active Comparator: 2; 1-MNA 90 mg daily: one active treatment capsule and two placebo capsules PO three times daily	Dietary supplement: 1-Methylnicotinamide (1-MNA); Following a 6-8-week placebo and dietary-controlled baseline period, 195 men and women will be randomized to receive placebo, 30 mg MNA or 90 mg MNA three times daily for twelve weeks.; Other Names: 1-MNA
Active Comparator: 3; 1-MNA 270 mg daily: three active treatment capsules PO three times daily.	Dietary supplement: 1-Methylnicotinamide (1-MNA); Following a 6-8-week placebo and dietary-controlled baseline period, 195 men and women will be randomized to receive placebo, 30 mg MNA or 90 mg MNA three times daily for twelve weeks.; Other Names: 1-MNA

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The percent change in total serum Triglycerides from baseline to end of study	12 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
The percent change in total cholesterol, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, high-density lipoprotein cholesterol , total apolipoprotein B , apolipoprotein A1 and TG/HDL-C ratio from baseline to end of study.	One year

Collaborators and Investigators

• Sponsor: Montreal Heart Institute
• Collaborators: Institut de Recherches Cliniques de Montreal; Royal Victoria Hospital, Canada; Queen Elizabeth II Health Sciences Centre; Hotel Dieu Hospital; Commonwealth Medical Clinic; Clinique des maladies lipidiques de Québec; Centre de médecine genique communautaire; Omnispec clinical research Inc; Manna Research; St. Jerome Medical Research Inc.; St Michael's Hospital Health Center; Cambridge Cardiac Care Centre; Maritime Research Center; Rhodin Recherche Clinique; First Line Medical Ltd; Diabetes Research, Vancouver General Hosp; The Allin Clinic; St Paul's Hospital Healthy Heart Clinical Trial; The Clinical Trials Centre; Recherche Invascor Inc; MSHJ Research Associates; Dr.Kim W Tan

Study record dates

Study Major Dates

• Study Start: September 1, 2007
• Primary Completion (Actual): October 1, 2008
• Study Completion (Actual): November 1, 2008

Study Registration Dates

• First Submitted: August 21, 2007
• First Submitted That Met QC Criteria: August 21, 2007
• First Posted (Estimate): August 23, 2007

Study Record Updates

• Last Update Posted (Actual): February 21, 2020
• Last Update Submitted That Met QC Criteria: February 20, 2020
• Last Verified: February 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Lipid Metabolism Disorders; Hyperlipidemias; Dyslipidemias; Hypertriglyceridemia
• Other Study ID Numbers: PNAI-MNA-001